EP2007346A1 - Forme pharmaceutique osmotique - Google Patents

Forme pharmaceutique osmotique

Info

Publication number
EP2007346A1
EP2007346A1 EP06851344A EP06851344A EP2007346A1 EP 2007346 A1 EP2007346 A1 EP 2007346A1 EP 06851344 A EP06851344 A EP 06851344A EP 06851344 A EP06851344 A EP 06851344A EP 2007346 A1 EP2007346 A1 EP 2007346A1
Authority
EP
European Patent Office
Prior art keywords
core
shell
dosage form
active ingredient
immediate release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06851344A
Other languages
German (de)
English (en)
Inventor
Harry S. Sowden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Consumer Inc
Original Assignee
McNeil PPC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McNeil PPC Inc filed Critical McNeil PPC Inc
Publication of EP2007346A1 publication Critical patent/EP2007346A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Definitions

  • This invention relates to dosage forms providing modified release of one or more active ingredients contained therein via an osmotic delivery system.
  • Modified release pharmaceutical dosage forms have long been used to optimize drug delivery and enhance patient compliance, especially by reducing the number of doses of medicine the patient must take in a day. In some instances, it is also desirable for a dosage form to deliver more than one drug at different rates or times. Modified release dosage forms should ideally be adaptable so that release rates and profiles can be matched to physiological and chronotherapeutic requirements. Because the onset and duration of the therapeutic efficacy of drugs vary widely, as do their absorption, distribution, metabolism, and elimination, it is often desirable to modify the release of different drugs in different ways, or to have a first dose of drug (active ingredient) immediately released from the dosage form, while a second dose of the same or a different drug is released in a modified, e.g. delayed, pulsatile, repeat action, controlled, sustained, prolonged, extended, or retarded manner.
  • a modified e.g. delayed, pulsatile, repeat action
  • a dosage form or drug delivery system
  • a controlled rate e.g. sustained, prolonged, extended or retarded release
  • diffusion erosion, and osmosis
  • modified release dosage forms provide a desired blood concentration versus time (pharmacokinetic, or PK) profile for the drug.
  • PK profile for a drug is governed by the rate of absorption of the drug into the blood, and the rate of elimination of the drug from the blood.
  • the drug To be absorbed into the blood (circulatory system), the drug must first be dissolved in the gastrointestinal fluids.
  • controlling the rate of dissolution i.e. drug release from the dosage form
  • the type of PK profile, and correspondingly, the type of dissolution or release profile desired depends on, 5 among other factors, the particular active ingredient and physiological condition being treated.
  • One particularly desirable PK profile is achieved by a dosage form that delivers a delayed release dissolution profile, in which the release of one or more doses of drug from the dosage form is delayed for a pre-determined time after contacting of the dosageo form by a liquid medium, such as for example, after ingestion by the patient.
  • the delay period (“lag time") can be followed either by prompt release of the active ingredient ("delayed burst"), or by sustained (prolonged, extended, or retarded) release of the active . ingredient ("delayed then sustained”).
  • U.S. Patent No. 5,464,633 discloses delayed-release dosage forms in which an external coating layer was applied by as compression coating process. The coating level ranged from 105 percent to 140 percent of the weight of the core in order to yield product with the desired time delayed profile.
  • One particularly desirable type of delayed release PK profile is obtained from a
  • pulsatile release profile in which for example, a first dose of a first drug is delivered, followed by a delay period ("lag time") during which there is substantially no release of o the first drug from the dosage form, followed by either prompt or sustained release of a subsequent dose of the same drug.
  • lag time a delay period
  • the first dose is released essentially immediately upon contacting of the dosage form with a liquid medium.
  • the delay period corresponds approximately to the time during5 which a therapeutic concentration of the first dose is maintained in the blood.
  • Pulsatile delivery systems are particularly useful for applications where a continuous release of drug is not ideal. Examples of this are drugs exhibiting first pass metabolism by the liver, drugs that induce biological tolerance, i.e.
  • One typical pulsatile dosage form design contains the first dose of drug in an exterior coating, or shell, while subsequent doses of drug are contained in underlying layers of subcoatings, or a central core.
  • PCT Publication No. WO 99/62496 discloses a dosage form comprising an immediate-release dose of drug contained within an overcoat applied onto the surface of the semi-permeable membrane of an osmotic dosage form.
  • dosage forms comprising an exterior drug coat that surrounds a semi-permeable wall, which in turn surrounds an internal compartment containing a second dose of drug, and comprises exit means for connecting the interior of the dosage form with the exterior environment of use. These dosage forms are designed to release drug immediately from the exterior coating, followed by a relatively short delay period, followed by a sustained release of drug from the internal compartment.
  • U.S. Patent No. 4,576,604 discloses an osmotic device (dosage form) comprising a drug compartment surrounded by a wall (coating) having a passageway therein. The wall may comprise an immediate release dose of drug, and the inner drug compartment may comprise a sustained release dose of drug.
  • Patent No. 4,449,983 discloses another osmotic device comprising two separately housed drugs that are separately dispensed from the device.
  • the device comprises two compartments, one for each drug, separated by a partition. Each compartment has an orifice for communicating with the exterior of the device.
  • U.S. Patent No. 5,738,874 discloses a 3-layer pharmaceutical compressed tablet capable of liberating one or more drugs at different release rates, in which an immediate release dose of active may be contained in a compressed coating layer, and in one embodiment, the outer compressed coating layer may function via an erosion mechanism to delay release of a second dose of active ingredient contained in the core.
  • the casing can be applied by various methods such as spraying, compression, or immersion, or the tablet parts can be inserted into a pre-formed casing.
  • Multilayer compressed tablets in stacked layer configurations necessarily require an impermeable partial coating (casing) in order to provide a pulsatile release profile.
  • Dosage forms have been previously designed with multiple cores housed in a single shell for the purpose of allowing flexibility in a dosing regimen.
  • PCT Publication No. WO 00/18447 describes a multiplex drug delivery system suitable for oral administration containing at least two distinct drug dosage packages, which exhibit equivalent dissolution profiles for an active agent when compared to one another and when compared to that of the entire multiplex drug delivery unit, and substantially enveloped by a scored compressed coating that allows the separation of the multiplex drug delivery system into individual drug dosage packages.
  • two immediate-release compartments are enveloped by a scored extended-release compartment. Active ingredient may be contained in only the extended release compartment, or additionally in the two immediate release compartments.
  • the multiplex drug delivery systems of this example are prepared by press coating the extended-release compartment to substantially envelop the immediate release compartments.
  • Published U.S. patent application 2003/0235616 describes a modified release dosage form comprising at least one active ingredient and at least two cores surrounded by a shell. The shell comprises at least one opening.
  • Published U.S. patent application 2003/0232082 describes a modified release dosage form comprising at least one active ingredient, a core having an outer surface, and a shell that resides upon at least a portion of the core outer surface and a shell that is semi-permeable such that the liquid medium diffuses through the shell to the core due to osmosis.
  • Osmotic dosage forms for delivering a drug to a fluid environment of use are known to the drug dispensing art.
  • U.S. Pat. No. 3,845,770 and in U.S. Pat. No. 3,916,899 an osmotic dosage form is disclosed comprising a semipermeable wall that surrounds a compartment comprising a drug.
  • the wall is permeable to the passage of fluid and there is a passageway through the wall for delivering the drug from the dosage form.
  • the dosage forms of these patents release the drug by fluid being imbibed through the wall into the compartment at a rate determined by the permeability of the wall and the osmotic pressure gradient across the wall to produce a solution of drug that is dispensed through the passageway from the dosage form.
  • These dosage forms are extraordinarily effective for delivering a drug that exhibits an osmotic pressure gradient across the wall against the fluid.
  • the dosage forms are effective also for delivering a drug mixed with an osmotically effective solute that is soluble in the fluid and exhibits an osmotic pressure gradient across the wall against an aqueous fluid.
  • osmotic dosage forms in these patents comprise a semipermeable wall that surrounds a compartment.
  • the compartment contains a drug formulation and an expandable hydrogel.
  • fluid is imbibed into the compartment where it contacts the drug formulation; thereby forming a dispensable formulation that is pushed by the expanding hydrogel from the dosage form.
  • U.S. Pat. No. 4,627,850 describes an osmotic capsule comprising a wall encapsulating and containing a drug formulation.
  • the drug formulation is delivered through a very small orifice manufactured without any expressed ratio to the dimensions of the osmotic capsule.
  • Improved dosage forms for providing modified release of active ingredient are described herein, particularly as osmotic drug delivery devices.
  • the present invention is directed, in one aspect, to a dosage form having a first immediate release core that contains at least one pharmaceutically active ingredient, an osmotic core that contains at least one pharmaceutically active ingredient that is the same or different from the pharmaceutically active ingredient provided in the first core, and a unitary shell that conforms and coats at least a substantial portion of both the first immediate release core and the osmotic core.
  • the shell material is substantially impermeable to the pharmaceutically active ingredient in the osmotic core.
  • at least one passageway can be provided through the shell to the immediate release core with sufficient size for immediate release of the active contained therein and at least one passageway can be provided through the unitary shell to the osmotic chamber.
  • the passageways can be provided with a fill material that is compositionaUy different from the shell.
  • the first immediate release core can be a multi-layer tablet.
  • the pore volume of the shell as applied to the dosage form is preferably less than 0.2 cc/g for pores having a diameter between about 0.5 to about 5 microns.
  • the present invention is directed, in another aspect, to a dosage form having a first immediate release core that contains at least one pharmaceutically active ingredient, an osmotic core that contains at least one pharmaceutically active ingredient that is the same or different from the pharmaceutically active ingredient provided in the first immediate release core, and a shell having distinct, compositionally different portions that as a whole conform and coat at least a substantial portion of both the first immediate release core and the osmotic core.
  • the shell has a major portion consisting essentially of material that is substantially impermeable to the pharmaceutically active ingredient in the osmotic chamber and a second portion of the shell that is in contact with the immediate release core that consists essentially of immediate release material. At least one passageway can be provided through the shell to the osmotic chamber.
  • the first immediate release core can be a compressed solid tablet.
  • the first immediate release core can be a multi-layer tablet.
  • AH portions of the shell can be substantially free of pores having a diameter of 0.5 to 5.0 microns.
  • the pore volume of all portions of the shell as applied to the dosage form is preferably less than 0.2 cc/g for pores having a diameter between about 0.5 to about 5 microns.
  • the present invention relates, in another aspect, to a dosage form having a first immediate release core that contains at least one pharmaceutically active ingredient, an osmotic core that contains at least one pharmaceutically active ingredient that is the same or different from the pharmaceutically active ingredient provided in the first immediate release core, and a unitary shell that conforms and coats at least a substantial portion of the first immediate release core and the osmotic core.
  • a portion of the shell provided over the immediate release core is sufficiently thin that it ruptures upon swelling of the immediate release core to release the active contained therein.
  • At least one passageway can be provided through the shell to the osmotic chamber.
  • the first immediate release core can be a compressed solid tablet.
  • the shell is preferably substantially free of pores having a diameter of 0.5 to 5.0 microns. Alternatively, the pore volume of the shell as applied to the dosage form is less than 0.2 cc/g for pores having a diameter between about 0.5 to about 5 microns.
  • the present invention further relates to a dosage form having a first immediate release core that contains a pharmaceutically active ingredient, an osmotic chamber that contains one pharmaceutically active ingredient that is the same or different from the pharmaceutically active ingredient provided in the first core, and a shell that consists essentially of an immediate release material and coats at least a substantial portion of the first immediate release core and the osmotic chamber.
  • the osmotic chamber includes a barrier layer that is substantially impermeable to the active ingredient contained therein. A passageway can be provided through the barrier layer.
  • the first immediate release core can be a compressed solid tablet.
  • the shell as applied to the dosage form is preferably substantially free of pores having a diameter of 0.5 to 5.0 microns.
  • the pore volume of shell as applied to the dosage form is less than 0.2 cc/g for pores having a diameter between about 0.5 to about 5 microns.
  • the present invention further relates to a dosage form having a first core that contains a pharmaceutically active ingredient, an osmotic chamber that contains one pharmaceutically active ingredient that is the same or different from the pharmaceutically active ingredient provided in the first core, and a shell having distinct, compositionally different portions that coat a substantial portion of the first core and osmotic chamber.
  • the first shell portion that is in contact with the first core provides an immediate release of the pharmaceutically active ingredient in the first core and the second shell portion in contact with the osmotic chamber produces a modified release profile.
  • the first immediate release core can be a compressed solid tablet or a multi-layer tablet. All portions of the shell are preferably substantially free of pores having a diameter of 0.5 to 5.0 microns. The pore volume of all portions of the shell as applied to the dosage form are preferably less than 0.2 cc/g for pores having a diameter between about 0.5 to about 5 microns.
  • the present invention further relates to a method for preparing a dosage form by providing a first immediate release core containing at least one pharmaceutically active ingredient and an osmotic core or an osmotic chamber containing at least one pharmaceutically active ingredient that is the same or different from the
  • the present invention also relates to a method for preparing a dosage form by providing a first immediate release core containing at least one pharmaceutically active l o ingredient and an osmotic core or an osmotic chamber containing at least one pharmaceutically active ingredient that is the same or different from the pharmaceutically active ingredient provided in the first core to a shell-forming module, and providing a shell having distinct portions and that conforms and coats at least a substantial portion of both the first immediate release core and the osmotic core or is osmotic chamber.
  • Figure 1 is a side view of an osmotic chamber.
  • Figures 2 and 3 illustrate a sectioned view of an osmotic chamber.
  • 2 o Figure 4 is an alternative embodiment of the present invention.
  • Figure 5 is an alternative embodiment of the present invention.
  • Figure 6 is an alternative embodiment of the present invention.
  • dosage form applies to any solid object or semi-solid 25 designed to contain a specific pre-determined amount (dose) of a certain ingredient, for example an active ingredient as defined below.
  • Suitable dosage forms may be pharmaceutical drug delivery systems, including those for oral administration, buccal administration, rectal administration, topical or mucosal delivery, or subcutaneous implants, or other implanted drug delivery systems; or compositions for delivering minerals, vitamins and other nutraceuticals', oral care agents, flavorants, and the like.
  • the dosage forms of the present invention are considered to be solid, however they may contain liquid or semi-solid components.
  • the dosage form is an orally administered system for delivering a pharmaceutical active ingredient to the gastro-intestinal tract of a human.
  • the shell is understood to be a material that is malleable, flowable and conformable such that a shell material, when applied, will have a surface that conforms to the shape of the element (whether a core or another underlying shell) over which it is applied.
  • the core in contrast, has a fixed, generally unitary shape that does not change significantly when introduced or provided in the dosage form.
  • a unitary shell is understood to mean a continuous layer of materials that has been provided over one or more components of the dosage form. It is possible for a unitary shell to be provided on the dosage form in multiple, separate steps provided the subsequent additions utilize substantially the same compositional materials.
  • the present invention is directed to a dosage form for delivering at least one active ingredient to a subject having a first immediate release core for a pharmaceutically active ingredient, an osmotic chamber comprising at least one core for a pharmaceutically active ingredient that can be the same or different from the immediate release core and an osmagent, and a shell that surrounds the first immediate release core and the osmotic chamber, wherein the osmotic chamber is surrounded, with the exception of an egress for controlled delivery of the pharmaceutically active ingredient, by an barrier layer that is impermeable to the pharmaceutically active ingredient contained therein.
  • the first immediate release core is completely surrounded by or embedded in the shell material that has immediate release properties.
  • the first immediate release core and the osmotic chamber are surrounded or embedded in a shell that provided a modified release profile.
  • the first immediate release core and the osmotic chamber are surrounded or embedded in a shell that provided a modified release profile while openings are provided through the shell in the vicinity of the first immediate release core.
  • the first immediate release core and the osmotic chamber are surrounded or embedded in a shell having distinct portions such that the shell in the vicinity of the first immediate release core has immediate release properties, while the shell provided over at least the egress, preferably over any exposed surface area of the osmotic chamber has a modified release profile.
  • FIGS 1 through 3 are illustrative of an osmotic chamber that can be manufactured as part of the present invention.
  • osmotic chamber 10 is manufactured with a semipermeable wall 14 that does not adversely affect drug 16, the components comprising osmotic chamber 10, and an animal, including a human patient host.
  • Semipermeable wall 14 is permeable to the passage of external fluid such as water and biological fluids, and it is substantially impermeable to the passage of drug 16.
  • Compartment 15 comprises an effective amount of a pharmaceutically active ingredient or drug represented by dots.
  • Drug 16 in one embodiment, is soluble to very soluble in an external fluid imbibed through semipermeable wall 14 into compartment 15, and drug 16 exhibits an osmotic pressure gradient across wall 14.
  • Drug 16 in another embodiment exhibits a limited solubility in fluid imbibed into compartment 15, and it exhibits a limited osmotic pressure gradient across wall 14.
  • drug 16 optionally mixed with an osmagent 17, presented as dashes, which osmagent 17 is soluble in the external fluid and it exhibits an osmotic pressure gradient across wall 14 for aiding in dispensing drug 16 from osmotic chamber 10.
  • Drug 16 can be present in compartment 15 with an optional member selected from the group consisting of a binder, dispersant, wetting agent, suspending agent, lubricant and dye, represented by wavy line 18.
  • a binder such as colloidal magnesium, silicon dioxide, and calcium silicate; binders like polyvinyl pyrrolidone, lubricants like magnesium stearate, and wetting agents such as fatty amines and fatty quaternary ammonium salts.
  • a dye can be present in the compartment 15 for aiding in identifying a drug 16 present in osmotic chamber 10.
  • Passageway 19 is a wide-passageway that is generally cylindrical. In the preferred manufacture, passageway 19 is positioned at the tip of the convex surface of the drug surface 20 of wall 12. The passageway area optionally can be as large as the cylindrical cross-section area of the chamber. Caplet passageway 19, in another manufacture comprises a multiplicity of orifices in convex surface 20, with the total area of the multiplicity of caplet passageways 19 less than the cross-sectional area of the oblong osmotic caplet 10 at its widest area.
  • FIG. 3 depicts osmotic chamber 10 comprising a body 11 having a lead end 12, rear end 13, wall 14 and compartment 15.
  • Osmotic core or alternatively compartment 15 comprises drug 16 and an osmopolymer 21, or an expandable driving member, identified by curve lines.
  • Osmopolymer 21 is in contact with the drug 16 composition.
  • the drug 16 composition layer and the osmopolymer 21 layer operate in union for delivering the maximum dose of drug 16 through opened passageway 19.
  • Compartment 15 optionally comprises a member 18 selected from the group consisting of a binder, dispersant, wetting agent, suspending agent, lubricant, and dye.
  • Osmotic chamber 10 comprises additionally an internal wall 22 that faces compartment 15 and is in layered arrangement with the internal surface of wall 14.
  • Internal wall 22 is non-toxic and it does not adversely affect drug 16 and other members 18 present in compartment 15.
  • Internal wall 22 is permeable to the passageway of aqueous and biological fluids, and it comprises a hydrophilic polymeric composition that swells in the presence of fluid imbibed into compartment 15.
  • the selectively semipermeable wall compositions are non-erodible, nontoxic, and they are insoluble in fluids.
  • Typical materials for forming wall 14 in one embodiment are cellulose esters, cellulose ethers and cellulose ester-ethers. These cellulosic polymers have a degree of substitution, D.S., on the anhydroglucose unit from greater than 0 up to 3 inclusive.
  • degree of substitution is meant the average number of hydroxyl groups originally present on the anhydroglucose unit comprising the cellulose polymer that are replaced by a substituting group.
  • Representative materials include a member selected from the group consisting of cellulose acylate, cellulose diacrylate, cellulose triacrylate, cellulose acetate, cellulose diacetate, cellulose triacetate, mono, di and tricellulose alkanylates, mono, di and tricellulose aroylates, and the like.
  • Exemplary polymers include cellulose acetate having a D.S. up to 1 and acetyl content up to 21%; cellulose acetate having an acetyl content of 32 to 39.8%: cellulose diacetate having a D.S.
  • More specific cellulosic polymers include cellulose propionate having a D.S. of 1.8 and a propionyl content of 39.2 to 45% and a hydroxyl content of 2.8 to 5.4%; cellulose acetate-butyrate having a D.S.
  • cellulose acetate butyrate having an acetyl content of 2 to 29%, a butyryl content of 17 to 53% and a hydroxyl content of 0.5 to 4.7%
  • cellulose triacylates having a D.S. of 2.9 to 3 such as cellulose trivalerate, cellulose trilaurate, cellulose tripalmitate, cellulose trisuccinate, and cellulose trioclanoate
  • cellulose diacylates having a D.S. of 2.2 to 2.6 such as cellulose disuccinate, cellulose dipalmitate, cellulose dioclanoate, cellulose dipentale, and the like.
  • Additional semipermeable polymers for wall 12 include acetaldehyde dimethyl acetate, cellulose acetate ethyl carbamate, cellulose acetate phthalate for use in environments having a low pH, cellulose acetate methyl carbamate, cellulose acetate dimethyl aminoacetate, semipermeable polyamides, semipermeable polyurethanes, semipermeable sulfonated polystyrenes, cross-linked selectively semipermeable polymers formed by the co-precipitation of a polyanion and a polycation as disclosed in U.S. Pat. Nos.
  • Inner wall 22, in contact with external wall 14 comprises in a presently preferred manufacturer gelatin.
  • the gelatin used for the present purpose comprises a viscosity of 10 to 40 millipoises and a bloom strength up to 150 grams; and gelatin comprising a bloom value of 160 to 250.
  • the inner wall 22 can comprises 100 weight percent gelatin, or in another manufacturer inner wall 22 can comprises 60 wt % to 99 wt % gelatin, and
  • a polysaccharide selected from the group consisting of agar, acacia, karaya, tragacanth, algin and guar.
  • Osmagent 17 that can be used for the purpose of this invention comprises inorganic and organic, preferably a solid compound that exhibits an osmotic pressure gradient across an external fluid across semipermeable wall 14.
  • the osmagents are known also as osmotically effective compounds, osmotic solutes, and osmotic fluid imbibing agents.
  • the osmagents are used by mixing the osmagent with drug 16 that has a limited solubility in the external fluid to provide an osmotic solid composition, that after fluid is imbibed into caplet, an osmotic drug solution that is hydrodynamically and osmotically delivered from osmotic chamber 10.
  • the phrase limited solubility as used herein means the drug has a solubility of less than 1 % by weight in an aqueous fluid present in the environment.
  • the osmagents are used by homogenously or heterogeneously mixing the osmagent with the drug and then changing the blend into a caplet or pressing the blend into a shape corresponding to the shape of osmotic chamber 10, which is then surrounded with semipermeable wall 14.
  • Osmagent 17 used for the purpose of this invention comprises a member selected from the group consisting of a salt, oxide, carbohydrate, acid, ester, magnesium sulfate, magnesium chloride, sodium chloride, potassium chloride, lithium chloride, potassium sulfate, sodium sulfate, lithium sulfate, lithium phosphate, sodium phosphate, potassium phosphate, potassium acid phosphate, calcium lactate, mannitol, urea, inositol, magnesium succinate, tartaric acid, carbohydrates such as raffinose, sucrose, glucose, lactose monohydrate, and a blend of fructose glucose.
  • the osmopolymer 17, operable for pushing drug 16 composition from caplet 10 comprises a hydrophilic polymer.
  • Hydrophilic polymers are known also as osmopolymers.
  • the osmopolymers interact with water and aqueous biological fluids and swell or expand to an equilibrium state.
  • the osmopolymers exhibit the ability to swell in water and retain a significant portion of the imbibed water within the polymer structure.
  • the osmopolymers swell or expand to a very high degree, usually exhibiting a 2 to 60- fold volume increase.
  • the osmopolymers can be noncross-linked or cross-linked.
  • the swellable, hydrophilic polymers are, in one presently preferred embodiment, lightly cross-linked, such as cross-links being formed by covalent or ionic bonds.
  • the osmopolymers can be of plant, animal or synthetic origin.
  • Hydrophilic polymers suitable for the present purpose include poly(hydroxyalkylmethacrylate) having a molecular weight of from 30,000 to 5,000,000; poly(vinylpyrrolidone) having molecular weight of from 10,000 to 360,000; anionic and cationic hydrogels; polyelectrolyte complexes, polyvinyl alcohol) having a low acetate residual, cross-linked with flyoxal, formaldehyde, or glutaraldehyde and having a degree of polymerization from 200 to 30,000; a mixture of methyl cellulose, cross-linked agar and carboxymethyl cellulose; a water insoluble, water swellable copolymer reduced by forming a dispersion of finely divided copolymer of
  • osmopolymers include hydrogel polymers such as Carbopol® acidic carboxy polymers generally having a molecular weight of 450,000 to 4,000,000; the sodium salt of Carbopol® acidic carboxy polymers and other metal salts; Cya ⁇ amer ® polyacrylamides; cross-linked water swellable indenemaleic anhydride polymers; Goodrite ® polyacrylic acid having, but not limited to, a molecular weight of 80,000 to
  • Osmotic core 15 can be prepared by compression as a multilayered tablet in known fashion.
  • Dosage form 40 comprises a first immediate release core 42 for a pharmaceutically active ingredient, osmotic chamber 10 described above, and a shell 44 that surrounds first immediate release core 42 and osmotic chamber 10.
  • One advantage of the present invention is the ability to provide a large immediate release of pharmaceutical active from the immediate release core relative to the commercially reasonable dosing levels that can be achieved in a coating layer.
  • Preferred dosing amounts for exemplary pharmaceutical actives are acetaminophen, at least 200 mg, preferably at least about 325 mg, alternatively about 500 mg; ibuprofen at least about 100 mg, preferably about 200 mg; aspirin at least about 100 mg, preferably about 325 mg; guafenisen at least about 100 mg, preferably about 200 mg; and calcium carbonate at least about 500 mg, preferably about 800 mg.
  • One embodiment of the present invention provides an immediate release core containing at least about 100 mg of pharmaceutically active ingredient, alternatively at least about 200 mg, still further at least about 325, and still further at least about 500 mg.
  • first immediate release core 42 is completely surrounded by or embedded in shell 44 that has immediate release properties.
  • first immediate release core 42 and osmotic chamber 10 are surrounded by or embedded in shell 44 that provides a modified release profile.
  • dosage form 50 comprises first immediate release core 52 and osmotic chamber 10, which are surrounded or embedded in shell 54 that provides a modified release profile and wherein at least one opening 56 is provided through the shell in the vicinity of first immediate release core 52.
  • dosage form 60 shown in Figure 6 comprises a first immediate release core 62 and osmotic chamber 10 that are surrounded or embedded in shell materials having distinct portions 66 and 68 such that first shell material 66 in the vicinity of first immediate release core 62 has immediate release properties, while second shell material 68 provided over osmotic chamber 10 has a modified release profile.
  • the active ingredient or ingredients are present in the dosage form in a therapeutically effective amount, which is an amount that produces the desired therapeutic response upon oral administration and can be readily determined by one skilled in the art. In determining such amounts, the particular active ingredient being administered, the bioavailability characteristics of the active ingredient, the dosing regimen, the age and weight of the patient, and other factors must be considered, as known in the art.
  • the dosage form comprises at least about 1 weight percent, for example, the dosage form comprises at least about 5 weight percent, say at least about 20 weight percent of a combination of one or more active ingredients.
  • a core comprises a total of at least about 25 weight percent (based on the weight of the core) of one or more active ingredients.
  • the active ingredient or ingredients may be present in the dosage form in any form.
  • the active ingredient may be dispersed at the molecular level, e.g. melted or dissolved, within the dosage form, or may be in the form of particles, which in turn may be coated or uncoated. If an active ingredient is in the form of particles, the particles (whether coated or uncoated) typically have an average particle size of about 1- 2000 microns.
  • Each core may be any solid form.
  • core refers to a material that is at least partially enveloped or surrounded by another material.
  • a core is a self-contained unitary object, such as a tablet or capsule.
  • a core comprises a solid
  • a core may be a compressed or molded tablet, hard or soft capsule, suppository, or a confectionery form such as a lozenge, nougat, caramel, fondant, or fat based composition.
  • a core or a portion thereof may be in the form of a semi-solid or a liquid in the finished dosage form.
  • a core may comprise a liquid filled capsule, or a semisolid fondant material.
  • the core preferably additionally comprises an enveloping component, such as a capsule shell, or a coating, for containing the flowable material.
  • a core comprises an enveloping component
  • the shell or shell portions of the present invention are in direct contact with the enveloping component of the core, which separates the shell from the flowable component of the, core.
  • the core may have one of a variety of different shapes. Each core may have the same or different physical dimensions, shape, etc. as the other cores.
  • a core has one or more major faces.
  • the core surface typically has opposing upper and lower faces formed by contact with the upper and lower punch faces in the compression machine.
  • the core surface typically further comprises a "belly- band" located between the upper and lower faces, and formed by contact with the die walls in the compression machine.
  • a core may also comprise a multilayer tablet.
  • at least one core is a compressed tablet having a hardness from about 2 to about 30 kp/cm 2 , e.g. from about 6 to about 25 kp/cm 2 .
  • Hardness is a term used in the art to describe the diametral breaking strength of either the core or the coated solid dosage form as measured by conventional pharmaceutical hardness testing equipment, such as a Schleuniger Hardness Tester. In order to compare values across different size tablets, the breaking strength must be normalized for the area of the break. This normalized value, expressed in kp/cm 2 , is sometimes referred in the art as tablet tensile strength.
  • all the cores in the dosage form comprise a compressed tablet having a hardness from about 2 to about 30 kp/cm 2 , e.g. from about 6 to about 25 kp/cm 2 .
  • Exemplary core shapes that may be employed include tablet shapes formed from compression tooling shapes described by 'The Elizabeth Companies Tablet Design Training Manual" (Elizabeth Carbide Die Co., Inc., p. 7 (McKeesport, Pa.) (incorporated herein by reference).
  • the cores may be prepared by any suitable method, including for example compression or molding, and depending on the method by which they are made, typically comprise active ingredient and a variety of excipients.
  • suitable excipients include fillers, binders, disintegrants, lubricants, glidants, and the like, as known in the art.
  • a core is made by compression and additionally confers modified release of an active ingredient contained therein, such core preferably further comprises a release-modifying compressible excipient.
  • Suitable fillers for use in making a core or core portion by compression include water-soluble compressible carbohydrates such as sugars, which include dextrose, sucrose, maltose, and lactose, sugar-alcohols, which include mannitol, sorbitol, maltitol, xylitol, starch hydrolysates, which include dextrins, and maltodextrins, and the like, water insoluble plastically deforming materials such as microcrystalline cellulose or other cellulosic derivatives, water-insoluble brittle fracture materials such as dicalcium phosphate, tricalcium phosphate and the like and mixtures thereof.
  • water-soluble compressible carbohydrates such as sugars, which include dextrose, sucrose, maltose, and lactose
  • sugar-alcohols which include mannitol, sorbitol, maltitol, xylitol
  • starch hydrolysates which include dextrins, and maltod
  • Suitable binders for making a core or core portion by compression include dry binders such as polyvinyl pyrrolidone, hydroxypropylmethylcellulose, and the like; wet binders such as water-soluble polymers, including hydrocolloids such as acacia, alginates, agar, guar gum, locust bean, carrageenan, carboxymethylcellulose, tara, gum arabic, tragacanth, pectin, xanthan, gellan, gelatin, maltodextrin, galactomannan, pusstulan, laminarin, scleroglucan, inulin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan, polyvinyl pyrrolidone, cellulosics, sucrose, starches, and the like; and derivatives and mixtures thereof.
  • dry binders such as polyvinyl pyrrolidone
  • Suitable disintegrants for making a core or core portion by compression include sodium starch glycolate, cross-linked polyvinylpyrrolidone, cross-linked carboxymethylcellulose, starches, microcrystalline cellulose, and the like.
  • Suitable lubricants for making a core or core portion by compression include long chain fatty acids and their salts, such as magnesium stearate and stearic acid, talc, glycerides and waxes.
  • Suitable glidants for making a core or core portion by compression include colloidal silicon dioxide, and the like.
  • Suitable release-modifying excipients for making a core or core portion by compression include swellable erodible hydrophilic materials, insoluble edible materials, pH-dependent polymers, and the like.
  • Suitable swellable erodible hydrophilic materials for use as release-modifying excipients for making a core or core portion by compression include: water swellable cellulose derivatives, polyalkylene glycols, thermoplastic polyalkylene oxides, acrylic polymers, hydrocolloids, clays, gelling starches, and swelling cross-linked polymers, and derivatives, copolymers, and combinations thereof.
  • suitable water swellable cellulose derivatives include sodium carboxymethylcellulose, cross-linked hydroxypropylcellulose, hydroxypropyl cellulose (HPC), hydroxypropylmethylcellulose (HPMC), hydroxyisopropylcellulose, hydroxybutylcellulose, hydroxyphenylcellulose, hydroxyethylcellulose (HEC), hydroxypentylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, hydroxypropylethylcellulose.
  • suitable polyalkylene glycols include polyethylene glycol.
  • suitable thermoplastic polyalkylene oxides include poly (ethylene oxide).
  • acrylic polymers include potassium methacrylate divinylbenzene copolymer, polymethylmethacrylate, CARBOPOL (high-molecular weight cross-linked acrylic acid homopolymers and copolymers), and the like.
  • suitable hydrocolloids include alginates, agar, guar gum, locust bean gum, kappa carrageenan, iota carrageenan, tara, gum arabic, tragacanth, pectin, xanthan gum, gellan gum, maltodextrin, galactomannan, pusstulan, laminarin, scleroglucan, gum arabic, inulin, pectin, gelatin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan.
  • Suitable clays include smectites such as bentonite, kaolin, and laponite; magnesium trisilicate, magnesium aluminum silicate, and the like, and derivatives and mixtures thereof.
  • suitable gelling starches include acid hydrolyzed starches, swelling starches such as sodium starch glycolate, and derivatives thereof.
  • suitable swelling cross-linked polymers include cross-linked polyvinyl pyrrolidone, cross-linked agar, and cross-linked carboxymethylcellulose sodium.
  • Suitable insoluble edible materials for use as release-modifying excipients for making a core or core portion by compression include water-insoluble polymers, and low-melting hydrophobic materials.
  • suitable water-insoluble polymers include ethylcellulose, polyvinyl alcohols, polyvinyl acetate, polycaprolactones, cellulose acetate and its derivatives, acrylates, methacrylates, acrylic acid copolymers; and the like and derivatives, copolymers, and combinations thereof.
  • Suitable low-melting hydrophobic materials include fats, fatty acid esters, phospholipids, and waxes.
  • suitable fats include hydrogenated vegetable oils such as for example cocoa butter, hydrogenated palm kernel oil, hydrogenated cottonseed oil, hydrogenated sunflower oil, and hydrogenated soybean oil; and free fatty acids and their salts.
  • suitable fatty acid esters include sucrose fatty acid esters, mono, di, and triglycerides, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tristearate, glyceryl trilaurylate, glyceryl myristate, GlycoWax-932, lauroyl macrogol-32 glycerides, and stearoyl macrogoI-32 glycerides.
  • Suitable phospholipids include phosphatidyl choline, phosphotidyl serene, phosphotidyl enositol, and phosphotidic acid.
  • suitable waxes include carnauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax; fat- containing mixtures such as chocolate; and the like.
  • Suitable pH-dependent polymers for use as release-modifying excipients for making a core or core portion by compression include enteric cellulose derivatives, for example hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate; natural resins such as shellac and zein; enteric acetate derivatives such as for example polyvinylacetate phthalate, cellulose acetate phthalate, acetaldehyde dimethylcellulose acetate; and enteric acrylate derivatives such as for example polymethacrylate-based polymers such as poly(methacrylic acid, methyl methacrylate) 1:2, which is commercially available from Rohm Pharma GmbH under the tradename EUDRAGIT S, and poly(methacrylic acid, methyl methacrylate) 1:1, which is commercially available from Rohm Pharma GmbH under the tradename EUDRAGIT L, and the like, and derivatives, salts, copolymers, and combinations thereof.
  • enteric cellulose derivatives
  • Suitable pharmaceutically acceptable adjuvants for making a core or core portion by compression include, preservatives; high intensity sweeteners such as aspartame, acesulfame potassium, sucralose, and saccharin; flavorants; colorants; antioxidants; surfactants; wetting agents; and the like and mixtures thereof.
  • a dry blending i.e. direct compression
  • wet granulation process may be employed, as known in the art.
  • a dry blending (direct compression) method the active ingredient or ingredients, together with the excipients, are blended in a suitable blender, than transferred directly to a compression machine for pressing into tablets.
  • a wet granulation method the active ingredient or ingredients, appropriate excipients, and a solution or dispersion of a wet binder (e.g. an aqueous cooked starch paste, or solution of polyvinyl pyrrolidone) are mixed and granulated.
  • a wet binder e.g. an aqueous cooked starch paste, or solution of polyvinyl pyrrolidone
  • a dry binder may be included among the excipients, and the mixture may be granulated with water or other suitable solvent.
  • Suitable apparatuses for wet granulation are known in the art, including low shear, e.g. planetary mixers; high shear mixers; and fluid beds, including rotary fluid beds.
  • the resulting granulated material is dried, and optionally dry-blended with further ingredients, e.g. adjuvants and/or excipients such as for example lubricants, colorants, and the like.
  • the final dry blend is then suitable for compression.
  • Methods for direct compression and wet granulation processes are known in the art, and are described in detail in, for example, Lachman, et al., The Theory and Practice of Industrial Pharmacy, Chapter 11 O ⁇ ed. 1986).
  • the dry-blended, or wet granulated, powder mixture is typically compacted into tablets using a rotary compression machine as known in the art, such as for example those commercially available from Fette America Inc., Rockaway, NJ, or Manesty
  • a metered volume of powder is filled into a die cavity, which rotates as part of a "die table" from the filling position to a compaction position where the powder is compacted between an upper and a lower punch to an ejection position where the resulting tablet is pushed from the die cavity by the lower punch and guided to an ejection chute by a stationary "take-off bar.
  • At least one core is prepared by the compression methods and apparatus described in copendi ⁇ g U.S. Patent 6,767,200, the disclosure of which is incorporated herein by reference.
  • the core is made using a rotary compression module comprising a fill zone, compression zone, and ejection zone in a single apparatus having a double row die construction as shown in Figure 6 of U.S.
  • the dies of the compression module are preferably filled using the assistance of a vacuum, with filters located in or near each die.
  • Immediate release and osmotic cores made by compression may be single or multi-layer, for example bi-layer, tablets.
  • the dosage form comprises multiple shell portions that are compositionally and/or functionally different.
  • compositionally different means having features that are readily distinguishable by qualitative or quantitative chemical analysis, physical testing, or visual observation.
  • the first and second shell portions may contain different ingredients, or different levels of the same ingredients, or the first and second shell portions may have different physical or chemical properties, different functional properties, or be visually distinct. Examples of physical or chemical properties that may be different include hydrophylicity, hydrophobicity, hygroscopicity, elasticity, plasticity, tensile strength, crystallinity, and density.
  • Examples of functional properties which may be different include rate and/or extent of dissolution of the material itself or of an active ingredient therefrom, rate of disintegration of the material, permeability to active ingredients, permeability to water or aqueous media, and the like.
  • Examples of visual distinctions include size, shape, topography, or other geometric features, color, hue, opacity, and gloss.
  • subcoatings are well known in the art and disclosed in, for example, United States Patent Nos. 3,185,626, which is incorporated by reference herein. Any composition suitable for film-coating a tablet may be used as a subcoating according to the present invention. Examples of suitable subcoatings are disclosed in United States Patent Nos. 4,683,256, 4,543,370, 4,643,894, 4,828,841 , 4,725,441 , 4,802,924, 5,630,871 , and 6,274,162, which are all incorporated by reference herein.
  • Additional suitable' subcoatings include one or more of the following ingredients: cellulose ethers such as hydroxypropylmethylcellulose, hydroxypropylcellulose, and hydroxyethylcellulose; polycarbohydrates such as xanthan gum, starch, and maltodextrin; plasticizers including for example, glycerin, polyethylene glycol, propylene glycol, dibutyl sebecate, triethyl citrate, vegetable oils such as castor oil, surfactants such as Polysorbate-80, sodium lauryl sulfate and dioctyl-sodium sulfosuccinate; polycarbohydrates, pigments, and opacifiers.
  • cellulose ethers such as hydroxypropylmethylcellulose, hydroxypropylcellulose, and hydroxyethylcellulose
  • polycarbohydrates such as xanthan gum, starch, and maltodextrin
  • plasticizers including for example, glycerin, polyethylene glycol
  • the dosage forms of the invention provide modified release of one or more active ingredients contained therein.
  • the active ingredient or ingredients may be found within one or more cores, the osmotic chamber(s), the shell, or portions or combinations thereof.
  • one or more active ingredients are contained in one or more cores and osmotic chamber(s). More preferably, at least one active ingredient is contained in each of the immediate release core and osmotic chamber.
  • modified release means the release of an active ingredient from a dosage form or a portion thereof in other than an immediate release fashion, i.e., other than immediately upon contact of the dosage form or portion thereof with a liquid medium.
  • types of modified release include delayed or controlled.
  • Types of controlled release include prolonged, sustained, extended, retarded, and the like.
  • Modified release profiles that incorporate a delayed release feature include pulsatile, repeat action, and the like.
  • suitable mechanisms for achieving modified release of an active ingredient include diffusion, erosion, surface area control via geometry and/or impermeable barriers, and other known mechanisms known.
  • At least one active ingredient is released from the first core in an immediate release fashion.
  • immediate release means the dissolution characteristics of an active ingredient meets USP specifications for immediate release tablets containing the active ingredient.
  • USP 24 specifies that in pH 5.8 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the acetaminophen contained in the dosage form is released therefrom within 30 minutes after dosing
  • USP 24 specifies that in pH 7.2 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the ibuprofen contained in the dosage form is released therefrom within 60 minutes after dosing. See USP 24, 2000 Version, 19-20 and 856 (1999).
  • the composition of the shell may function to modify the release therethrough of an active ingredient contained in an underlying core.
  • the shell may function to delay release of an active ingredient from an underlying core.
  • the shell may function to sustain, extend, retard, or prolong the release of at least one active ingredient from the second (distally located) core.
  • the immediate release of the active ingredient in the first core is provided by one or more openings in the shell suitable to provide immediate release. A plurality of openings having a diameter of least lmm (1000 microns) produces the desired flow characteristics.
  • the immediate release of the active ingredient in the first core is provided through the shape of the core.
  • a core can be provided in a position to cause the shell to rupture by ensuring that the shell is thinner on the side of the immediate release core.
  • the thickness of the coating suitable for rupture is less than lmm (1000 microns), preferably less than 500 microns.
  • the immediate release of the first core is provided through the addition of a water soluble fill material embedded in one portion of the shell in proximity to the immediate release core.
  • the shell comprises a release modifying moldable excipient, such as, but not limited to, swellable erodible hydrophilic materials described above.
  • the dosage form is substantially free (i.e.
  • charge control agents refers to a material having a charge control function, such as those used for electrostatic deposition of coatings onto substrates.
  • charge control agents include metal salicylates, for example zinc salicylate, magnesium salicylate and calcium salicylate; quaternary ammonium salts; benzalkonium chloride; benzethonium chloride; trimethyl tetradecyl ammonium bromide (cetrimide); and cyclodextrins and their adducts.
  • one or more active ingredients contained in the second core are released in a controlled, sustained, prolonged, or extended manner beginning initially upon contact of the dosage for with a liquid medium, with or without a substantial preceding lag time, e.g. release of at least one active ingredients begins within 30 minutes, e.g. within 15 minutes, say within 10 minutes, of contact of the dosage form with a liquid medium.
  • the shell itself e.g. a portion thereof, or an outer coating thereon may also contain active ingredient.
  • active ingredient will be released immediately from the dosage form upon ingestion, or contacting of the dosage form with a liquid medium.
  • such active ingredient will be released in a controlled, sustained, prolonged, or extended fashion upon ingestion, or contacting of the dosage form with a liquid medium.
  • the cores, the shell, the fill material or any portions thereof, or all are prepared by molding.
  • the cores, the shell, the fill material or all may be made by solvent-based molding or solvent-free molding.
  • the core, the shell, the fill material or all are made from a flowable material optionally comprising active ingredient.
  • the flowable material may be any edible material that is flowable at a temperature between about 37°C and 25O 0 C, and that is solid, semi-solid, or can form a gel at a temperature between about -10°C and about 35°C.
  • the flowable material When it is in the fluid or flowable state, the flowable material may comprise a dissolved or molten component for solvent-free molding, or optionally a solvent such as for example water or organic solvents, or combinations thereof, for solvent-based molding.
  • the solvent may be partially or substantially removed by drying.
  • solvent-based or solvent-free molding is performed to produce the core and/or shell via thermal setting molding using the method and apparatus described in published U.S. patent application 2003-0124183 Al, the disclosure of which is incorporated herein by reference.
  • a core a shell, a fill material or all are formed by injecting flowable form into a molding chamber.
  • the flowable material preferably comprises a thermal setting material at a temperature above its melting point but below the decomposition temperature of any active ingredient contained therein.
  • the flowable material is cooled and solidifies in the molding chamber into a shaped form (i.e., having the shape of the mold).
  • the flowable material may comprise solid particles suspended in a molten matrix, for example a polymer matrix.
  • the flowable material may be completely molten or in the form of a paste.
  • the flowable material may comprise an active ingredient dissolved in a molten material in the case of solvent-free molding.
  • the flowable material may be made by dissolving a solid in a solvent, which solvent is then evaporated after the molding step in the case of solvent-based molding.
  • thermal cycle molding module having the general configuration shown in Figure 3 therein is employed.
  • the thermal cycle molding module comprises a rotor around which a plurality of mold units are disposed.
  • the thermal cycle molding module includes a reservoir for holding flowable material to make the core.
  • the thermal cycle molding module is provided with a temperature control system for rapidly heating and cooling the mold units.
  • the mold units may comprise center mold assemblies, upper mold assemblies, and lower mold assemblies that mate to form mold cavities having a desired shape, for instance of a core or a shell surrounding one or more cores.
  • the shell or fill material is applied to the dosage form using a thermal cycle molding apparatus of the general type of published U.S. application US 2003-0086973 Al comprising rotatable center mold assemblies, lower mold assemblies and upper mold assemblies. Cores and osmotic chambers are continuously fed to the mold assemblies.
  • Shell or fill flowable material which is heated to a flowable state in reservoir, is injected into the mold cavities created by the closed mold assemblies holding the cores. The temperature of the shell or fill flowable material is then decreased, hardening it around the cores and osmotic chambers. The mold assemblies open and eject the finished dosage forms. Shell coating is performed in two steps, each half of the dosage forms being coated separately as shown in the flow diagram published U.S. patent application 2003-0068367 Al via rotation of the center mold assembly.
  • the mold assemblies for applying the shell are provided with two or more cavities to accommodate the desired number of cores in the dosage form.
  • a wall preferably made of rubber or metal, separates the cavities and the overall shape of the cavities conform to the shape of the cores.
  • the shell is applied to the dosage form using a zero cycle molding apparatus of the general type of published U.S. application US , MCP5O18 (serial number 10/677,984) comprising rotatable center mold assemblies, lower mold assemblies and upper mold assemblies. Cores and osmotic chambers are continuously fed to the mold assemblies. Shell flowable material, which is heated to a flowable state in reservoir, is injected into the mold cavities created by the closed mold assemblies holding the cores and osmotic chambers. The mold assemblies open and eject the finished dosage forms. Shell coating is preferably performed in two steps, each half of the dosage forms being coated separately via rotation of the center mold assembly.
  • the mold assemblies for applying the shell are provided with two or more cavities to accommodate the desired number of cores and osmotic chambers in the dosage form.
  • a wall preferably made of rubber or metal, separates the cavities and the overall shape of the cavities conform to the shape of the cores.
  • the compression module of U.S. Patent 6,767,200 may be employed to make cores.
  • the shell may be made applied to these cores and osmotic chambers using a thermal cycle molding module as described above.
  • a transfer device may be used to transfer the cores and osmotic chambers from the compression module to the molding module.
  • Such a transfer device may have the structure shown published U.S. patent application 2003-0068367 Al.
  • the device comprises a plurality of transfer units attached in cantilever fashion to a belt. The transfer device rotates and operates in sync with the compression module and the molding module to which it is coupled. Transfer units comprise retainers for holding cores and osmotic chambers as they travel around the transfer device.
  • Each transfer unit comprises multiple retainers for holding multiple cores and osmotic chambers side by side.
  • the space between the retainers within each transfer unit is adjusted via a cam track/cam follower mechanism as the transfer units move around the transfer device.
  • the cores and osmotic chambers are grouped together for placement in a single dosage form, which have been held within a single transfer unit, are properly spaced from one another and ready to be fed into the mold assemblies.
  • the cores may comprise a single layer or multiple layers.
  • Suitable thermoplastic materials for use in or as the flowable material include both water-soluble and water insoluble polymers that are generally linear, not crosslinked, and not strongly hydrogen bonded to adjacent polymer chains.
  • suitable thermoplastic materials include: thermoplastic water-swellable cellulose derivatives, thermoplastic water insoluble cellulose derivatives, thermoplastic vinyl polymers, thermoplastic starches, thermoplastic polyalkylene glycols, thermoplastic polyalkylene oxides, and amorphous sugar-glass, and the like, and derivatives, copolymers, and combinations thereof.
  • suitable thermoplastic water swellable cellulose derivatives include hydroxypropyl cellulose (HPC), ' hydroxypropylmethyl cellulose (HPMC), methyl cellulose (MC).
  • thermoplastic water insoluble cellulose derivatives examples include cellulose acetate (CA), ethyl cellulose (EC), cellulose acetate butyrate (CAB), cellulose propionate.
  • suitable thermoplastic vinyl polymers include polyvinyl alcohol (PVA) and polyvinyl pyrrolidone (PVP).
  • suitable thermoplastic starches are disclosed for example in U.S. Patent No. 5,427,614.
  • suitable thermoplastic polyalkylene glycols include polyethylene glycol.
  • suitable thermoplastic polyalkylene oxides include polyethylene oxide having a molecular weight from about 100,000 to about 900,000 Daltons.
  • Other suitable thermoplastic materials include sugar in the form on an amorphous glass such as that used to make hard candy forms.
  • any film former known in the art is suitable for use in the flowable material.
  • suitable film formers include, but are not limited to, film-forming water- soluble polymers, film-forming proteins, film-forming water insoluble polymers, and film-forming pH-dependent polymers.
  • the film-former for making the core or shell or portion thereof by molding may be selected from cellulose acetate, ammonium methacrylate copolymer type B, shellac, hydroxypropylmethylcellulose, and polyethylene oxide, and combinations thereof.
  • Suitable film-forming water soluble polymers include water soluble vinyl polymers such as polyvinyl alcohol (PVA); water soluble polycarbohydrates such as hydroxypropyl starch, hydroxyethyl starch, pullulan, methylethyl starch, carboxymethyl starch, pre-gelatinized starches, and film-forming modified starches; water swellable cellulose derivatives such as hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC), methyl cellulose (MC), hydroxyethylmethylcellulose (HEMC), hydroxybutylmethylcellulose (HBMC), hydroxyethylethylcellulose (HEEC), and hydroxyethylhydroxypropylmethyl cellulose (HEMPMC); water soluble copolymers such as methacrylic acid and methacrylate ester copolymers, polyvinyl alcohol and polyethylene glycol copolymers, polyethylene oxide and polyvinylpyrrolidone copolymers; and derivatives and combinations thereof.
  • Suitable film-forming proteins may be natural or chemically modified, and include gelatin, whey protein, myofibrillar proteins, coagulatable proteins such as albumin, casein, caseinates and casein isolates, soy protein and soy protein isolates, zein; and polymers, derivatives and mixtures thereof.
  • Suitable film-forming water insoluble polymers include for example ethylcellulose, polyvinyl alcohols, polyvinyl acetate, polycaprolactones, cellulose acetate and its derivatives, acrylates, methacrylates, acrylic acid copolymers; and the like and derivatives, copolymers, and combinations thereof.
  • Suitable film-forming pH-dependent polymers include enteric cellulose derivatives, such as for example hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate; natural resins, such as shellac and zein; enteric acetate derivatives such as for example polyvinylacetate phthalate, cellulose acetate phthalate, acetaldehyde dimethylcellulose acetate; and enteric acrylate derivatives such as for example polymethacrylate-based polymers such as poly(methacrylic acid, methyl methacrylate) 1 :2, which is commercially available from Rohm Pharma GmbH under the tradename, EUDRAGIT S, and poly(methacrylic acid, methyl methacrylate) 1:1, which is commercially available from Rohm Pharma GmbH under the tradename, EUDRAGIT L, and the like, and derivatives, salts, copolymers, and combinations thereof.
  • enteric cellulose derivatives such as for example hydroxypropyl
  • HPMC 2910 is a cellulose ether having a degree of substitution of about 1.9 and a hydroxypropyl molar substitution of 0.23, and containing, based upon the total weight of the compound, from about 29% to about 30% methoxyl groups and from about 7% to about 12% hydroxylpropyl groups.
  • HPMC 2910 is commercially available from the Dow Chemical Company under the tradename METHOCEL E.
  • METHOCEL E5 which is one grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 4 to 6 cps (4 to 6 millipascal-seconds) at 20°C in a 2% aqueous solution as determined by a Ubbeiohde viscometer.
  • METHOCEL E6 which is another grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 5 to 7 cps (5 to 7 millipascal-seconds) at 20 0 C in a 2% aqueous solution as determined by a Ubbeiohde viscometer.
  • METHOCEL E15 which is another grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 15000 cps (15 millipascal-seconds) at 20 0 C in a 2% aqueous solution as determined by a Ubbeiohde viscometer.
  • degree of substitution means the average number of substiruent groups attached to an anhydroglucose ring
  • hydroxypropyl molar substitution means the number of moles of hydroxypropyl per mole anhydroglucose.
  • modified starches include starches that have been modified by crosslinking, chemically modified for improved stability or optimized performance, or physically modified for improved solubility properties or optimized performance. Examples of chemically modified starches are well known in the art and typically include those starches that have been chemically treated to cause replacement of some of its hydroxyl groups with either ester or ether groups. Crosslinking, as used herein, may occur in modified starches when two hydroxyl groups on neighboring starch molecules are chemically linked.
  • pre-gelatinized starches or “instantized starches” refers to modified starches that have been pre-wetted, then dried to enhance their cold-water solubility.
  • Suitable modified starches are commercially available from several suppliers such as, for example, A.E. Staley Manufacturing Company, and National Starch & Chemical Company.
  • One suitable film forming modified starch includes the pre-gelatinized waxy maize derivative starches that are commercially available from National Starch & Chemical Company under the tradenames PURITY GUM and FILMSET, and derivatives, copolymers, and mixtures thereof.
  • Such waxy maize starches typically contain, based upon the total weight of the starch, from about 0 percent to about 18 percent of amylose and from about 100% to about 88% of amylopectin.
  • suitable film forming modified starches include the hydroxypropylated starches, in which some of the hydroxyl groups of the starch have been etherified with hydroxypropyl groups, usually via treatment with propylene oxide.
  • a suitable hydroxypropyl starch that possesses film-forming properties is available from Grain Processing Company under the tradename, PURE-COTE B790.
  • Suitable tapioca dextrins for use as film formers include those available from National Starch & Chemical Company under the tradenames CRYSTAL GUM or K-
  • modified food starch derived from tapioca which is available from National Starch and Chemical under the tradename PURITY GUM 40, and copolymers and mixtures thereof.
  • any thickener known in the art is suitable for use in the flowable material of the present invention.
  • thickeners include but are not limited to hydrocolloids (also referred to herein as gelling polymers), clays, gelling starches, and crystallizable carbohydrates, and derivatives, copolymers and mixtures thereof.
  • hydrocolloids also referred to herein as gelling polymers
  • suitable hydrocolloids such as alginates, agar, guar gum, locust bean, carrageenan, tara, gum arabic, tragacanth, pectin, xanthan, gellan, maltodextrin, galactomannan, pusstulan, laminarin, scleroglucan, gum arabic, inulin, pectin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan.
  • suitable clays include smectites such as bentonite, kaolin, and laponite; magnesium trisilicate, magnesium aluminum silicate, and the like, and derivatives and mixtures thereof.
  • suitable gelling starches include acid hydrolyzed starches, and derivatives and mixtures thereof.
  • Additional suitable thickening hydrocolloids include low-moisture polymer solutions such as mixtures of gelatin and other hydrocolloids at water contents up to about 30%, such as for example those used to make "gummy" confection forms.
  • Additional suitable thickeners include crystallizable carbohydrates, and the like, and derivatives and combinations thereof. Suitable crystallizable carbohydrates include the monosaccharides and the oligosaccharides.
  • aldohexoses e.g., the D and L isomers of allose, altrose, glucose, mannose, gulose, idose, galactose, talose
  • ketohexoses e.g., the D and L isomers of fructose and sorbose along with their hydrogenated analogs: e.g., glucitol (sorbitol), and mannitol are preferred.
  • the 1,2-disaccharides sucrose and trehalose the 1,4-disaccharides maltose, lactose, and cellobiose, and the 1,6-disaccharides gentiobiose and melibiose, as well as the trisaccharide raffinose are preferred along with the isomerized form of sucrose known as isomaltulose and its hydrogenated analog isomalt.
  • Other hydrogenated forms of reducing disaccharides such as maltose and lactose
  • maltitol and lactitol are also preferred.
  • the hydrogenated forms of the aldopentoses e.g., D and L ribose, arabinose, xylose, and lyxose and the hydrogenated forms of the aldotetroses: e.g., D and L erythrose and throse are preferred and are exemplified by xylitol and erythritol, respectively.
  • the flowable material comprises gelatin as a gelling polymer.
  • Gelatin is a natural, thermogelling polymer. It is a tasteless and colorless mixture of derived proteins of the albuminous class that is ordinarily soluble in warm water.
  • Two types of gelatin - Type A and Type B - are commonly used.
  • Type A gelatin is a derivative of acid-treated raw materials.
  • Type B gelatin is a derivative of alkali-treated raw materials.
  • the flowable material is an aqueous solution comprising 20% 275 Bloom pork skin gelatin, 20% 250 Bloom Bone Gelatin, and approximately 60% water.
  • Suitable xanthan gums include those available from CP. Kelco Company under the tradenames KELTROL 1000, XANTROL 180, or K9B310.
  • Suitable clays include smectites such as bento ⁇ ite, kaolin, and laponite; magnesium trisilicate, magnesium aluminum silicate, and the like, and derivatives and mixtures thereof.
  • Acid-hydrolyzed starch is one type of modified starch that results from treating a starch suspension with dilute acid at a temperature below the gelatinization point of the starch. During the acid hydrolysis, the granular form of the starch is maintained in the starch suspension, and the hydrolysis reaction is ended by neutralization, filtration and drying once the desired degree of hydrolysis is reached. As a result, the average molecular size of the starch polymers is reduced. Acid-hydrolyzed starches (also known as “thin boiling starches”) tend to have a much lower hot viscosity than the same native starch as well as a strong tendency to gel when cooled.
  • Gelling starches include those starches that, when combined with water and heated to a temperature sufficient to form a solution, thereafter form a gel upon cooling to a temperature below the gelation point of the starch.
  • gelling starches include, but are not limited to, acid hydrolyzed starches such as that available from Grain Processing Corporation under the tradename PURE-SET B950; hydroxypropyl distarch phosphate such as that available from Grain Processing Corporation under the tradename, PURE-GEL B990, and mixtures thereof.
  • Suitable low-melting hydrophobic materials include fats, fatty acid esters, phospholipids, and waxes.
  • suitable fats include hydrogenated vegetable oils such as for example cocoa butter, hydrogenated palm kernel oil, hydrogenated cottonseed oil, hydrogenated sunflower oil, and hydrogenated soybean oil; and free fatty acids and their salts.
  • Suitable fatty acid esters include sucrose fatty acid esters, mono, di, and triglycerides, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tristearate, glyceryl trilaurylate, glyceryl myristate, GlycoWax- 932, lauroyl macrogol-32 glycerides, and stearoyl macrogol-32 glycerides.
  • suitable phospholipids include phosphotidyl choline, phosphotidyl serene, phosphotidyl enositol, and phosphotidic acid.
  • Suitable waxes include carnauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax; fat-containing mixtures such as chocolate; and the like.
  • Suitable non-crystallizable carbohydrates include non-crystallizable sugars such as polydextrose, and starch hydrolysates, e.g. glucose syrup, corn syrup, and high fructose corn syrup; and non-crystallizable sugar-alcohols such as maltitol syrup.
  • Suitable solvents for optional use as components of the flowable material for making the core or the shell by molding include water; polar organic solvents such as methanol, ethanol, isopropanol, acetone, and the like; and non-polar organic solvents such as methylene chloride, and the like; and mixtures thereof.
  • the flowable material for making cores, the shell, or fill material by molding may optionally comprise adjuvants or excipients, which may comprise up to about 30% by weight of the flowable material.
  • adjuvants or excipients include plasticizers, detackifiers, humectants, surfactants, anti-foaming agents, colorants, flavorants, sweeteners, opacifiers, and the like.
  • Suitable plasticizers for making the core, the shell, or a portion thereof, by molding include, but not be limited to polyethylene glycol; propylene glycol; glycerin; sorbitol; triethyl citrate; tributyl citrate; dibutyl sebecate; vegetable oils such as castor oil, rape oil, olive oil, and sesame oil; surfactants such as Polysorbates, sodium lauryl sulfates, and dioctyl-sodium sulfosuccinates; mono acetate of glycerol; diacetate of glycerol; triacetate of glycerol; natural gums; triacetin;' acetyltributyl citrate; diethyloxalate; diethylmalate; diethyl fumarate; diethylmalonate; dioctylphthalate; dibutylsuccinate; glyceroltributyrate; hydrogenated castor oil;
  • the plasticizer is triethyl citrate.
  • the shell is substantially free of plasticizers, i.e. contains less than about 1%, say less than about 0.01% of plasticizers.
  • the shell typically comprises at least about 30 percent, e.g. at least about 45 percent by weight of a thermal-reversible carrier.
  • the shell may optionally further comprise up to about 55 weight percent of a release-modifying excipient.
  • the shell may optionally further comprise up to about 30 weight percent total of various plasticizers, adjuvants and excipients.
  • the release modifying excipient is preferably selected from swellable, erodible hydrophilic materials.
  • the shell typically comprises at least about 10 weight percent, e.g. at least about 12 weight percent or at least about 15 weight percent or at least about 20 weight percent or at least about 25 weight percent of a film-former.
  • the shell may optionally further comprise up to about 55 weight percent of a release-modifying excipient.
  • the shell may again also optionally further comprise up to about 30 weight percent total of various plasticizers, adjuvants, and excipients.
  • the term "substantially conformally” means that the inner surface of the shell has peaks and valleys or indentations and protrusions corresponding substantially inversely to the peaks and valleys of the outer surface of the core.
  • the indentations and protrusions typically have a length, width, height or depth in one dimension of greater than 10 microns, say greater than 20 microns, and less than about 30,000 microns, preferably less than about 2000 microns.
  • the total weight of the shell is preferably about 20 percent to about 400 percent of the total weight of the cores.
  • the total weight of the shell is typically from about 50 percent to about 400 percent, e.g. from about 75 percent to about 400 percent, or about 100 percent to about 200 percent of the total weight of the cores.
  • the total weight of the shell is typically from about 20 percent to about 100 percent of the total weight of the 5 cores.
  • the thickness of the shell is important to the release properties of the dosage form. Typical shell thicknesses that may be employed are about 50 to about 4000 microns. In certain preferred embodiments, the shell has a thickness of less than 800 microns. In embodiments wherein the shell portion is prepared by a solvent-free molding i o process, the shell portion typically has a thickness of about 500 to about 4000 microns, e.g. about 500 to about 2000 microns, say about 500 to about 800 microns, or about 800 to about 1200 microns. In embodiments wherein the shell portion is prepared by a solvent-based molding process, the shell portion typically has a thickness of less than about 800 microns, e.g. about 100 to about 600 microns, say about 150 to about 400
  • the dosage form comprises first and second cores and first and second shell portions, and at least one of the shell portions has a thickness of less than about 800 microns, e.g. about 100 to about 600 microns, e.g. about 150 to about 400 microns.
  • the shell is prepared by molding
  • the fill or shell materials are typically substantially free of pores in the diameter range of 0.5 to 5.0 microns, i.e. has a pore volume in the pore diameter range of 0.5 to 5.0 microns of less than about 0.02 cc/g, preferably less than about 0.01 cc/g, more preferably less than about 0.005 cc/g.
  • Typical compressed materials have pore volumes in this diameter range of more than about 0.02
  • Pore volume, pore diameter and density may be determined using a Quantachrome Instruments PoreMaster 60 mercury intrusion porosimeter and associated computer software program known as "Porowin.” The procedure is documented in the Quantachrome Instruments PoreMaster Operation Manual.
  • the PoreMaster determines both pore volume and pore diameter of a solid or powder by forced intrusion of a non- wetting liquid (mercury), which involves evacuation of the sample in a sample cell (penetrometer), filling the cell with mercury to surround the sample with mercury, applying pressure to the sample cell by: (i) compressed air (up to 50 psi maximum); and
  • a hydraulic (oil) pressure generator up to 60000 psi maximum. Intruded volume is measured by a change in the capacitance as mercury moves from outside the sample into its pores under applied pressure.
  • the flowable material may comprise a thermal-reversible carrier.
  • Suitable thermal-reversible carriers for use in making a core, the shell or both by molding are thermoplastic materials typically having a melting point below about 110 0 C, more preferably between about 20 and about 100 0 C.
  • suitable thermal-reversible carriers for solvent-free molding include thermoplastic polyalkylene glycols, thermoplastic polyalkylene oxides, low melting hydrophobic materials, thermoplastic polymers, thermoplastic starches, and the like.
  • Preferred thermal-reversible carriers include polyethylene glycol and polyethylene oxide.
  • Suitable thermoplastic polyalkylene glycols for use as thermal- reversible carriers include polyethylene glycol having molecular weight from about 100 to about 20,000, e.g. from about 100 to' about 8,000 Daltons.
  • Suitable thermoplastic polyalkylene oxides include polyethylene oxide having a molecular weight from about 100,000 to about 900,000 Daltons.
  • Suitable low-melting hydrophobic materials for use as thermal-reversible carriers include fats, fatty acid esters, phospholipids, and waxes which are solid at room temperature, fat-containing mixtures such as chocolate; and the like.
  • suitable fats include hydrogenated vegetable oils such as for example cocoa butter, hydrogenated palm kernel oil, hydrogenated cottonseed oil, hydrogenated sunflower oil, and hydrogenated soybean oil; and free fatty acids and their salts.
  • Suitable fatty acid esters include sucrose fatty acid esters, mono, di, and triglycerides, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tristearate, glyceryl trilaurylate, glyceryl myristate, GlycoWax- 932, lauroyl macrogol-32 glycerides, and stearoyl macrogol-32 glycerides.
  • suitable phospholipids include phosphatidyl choline, phosphotidyl serene, phosphotidyl enositol, and phosphotidic acid.
  • suitable waxes that are solid at room temperature include carnauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax.
  • Suitable thermoplastic polymers for use as thermal-reversible carriers include thermoplastic water swellable cellulose derivatives, thermoplastic water insoluble polymers, thermoplastic vinyl polymers, thermoplastic starches, and thermoplastic resins, and combinations thereof.
  • Suitable thermoplastic water swellable cellulose derivatives include hydroxypropylmethyl cellulose (HPMC), methyl cellulose (MC), carboxymethylcellulose (CMC), cross-linked hydroxypropylcellulose, hydroxypropyl cellulose (HPC), hydroxybutylcellulose (HBC), hydroxyethylcellulose (HEC), hydroxypropylethylcellulose, hydroxypropylbutylcellulose, hydroxypropylethylcellulose, and salts, derivatives, copolymers, and combinations thereof.
  • HPMC hydroxypropylmethyl cellulose
  • MC methyl cellulose
  • CMC carboxymethylcellulose
  • HPC hydroxypropyl cellulose
  • HBC hydroxybutylcellulose
  • HEC hydroxyethylcellulose
  • thermoplastic water insoluble polymers include ethyicellulose, polyvinyl alcohols, polyvinyl acetate, polycaprolactones, cellulose acetate and its derivatives, acrylates, methacrylates, acrylic acid copolymers, and the like and derivatives, copolymers, and combinations thereof.
  • Suitable thermoplastic vinyl polymers include polyvinylacetate, polyvinyl alcohol, and polyvinyl pyrrolidone (PVP). Examples of suitable thermoplastic starches for use as thermal-reversible carriers are disclosed for example in U.S. Patent No. 5,427,614.
  • the thermal-reversible carrier for making a core by molding is selected from polyalkylene glycols, polyalkylene oxides, and combinations thereof.
  • the shell comprises an active ingredient intended to have immediate release from the dosage form, the shell is preferably prepared via solvent-free molding.
  • a thermaJ-reversible carrier is employed in the flowable material to make the shell, said thermal-reversible carrier preferably selected from polyethylene glycol with weight average molecular weight from about
  • the shell, or a shell portion may function as a diffusional membrane which contains pores through which fluids can enter the dosage form, contact and dissolve active ingredient in the core, which can then be released in a sustained, extended, prolonged or retarded manner.
  • the rate of release of active ingredient from an underlying core portion will depend upon the total pore area in the shell portion, the path length of the pores, and the solubility and diffusivity of the active ingredient (in addition to its rate of release from the core portion itself).
  • the release of the active ingredient from the dosage form may be described as controlled, prolonged, sustained or extended.
  • the contribution to active ingredient dissolution from the shell may follow zero-order, first-order, or square root of time kinetics.
  • the shell portion preferably comprises a release modifying moldable excipient comprising a combination of a pore former and an insoluble edible material, for example a film forming water insoluble polymer.
  • the shell portion may comprise a thermal-reversible carrier that functions by dissolving and forming pores or channels through which the active ingredient may be liberated.
  • the shell or a shell portion functions as an eroding matrix from which active ingredient dispersed in the shell is liberated by the dissolution of successive layers of the shell surface.
  • the rate of active ingredient release will depend on the dissolution rate of the matrix material in the shell or shell portion.
  • Particularly useful matrix materials for providing surface erosion include those that first absorb liquid, then swell and/or gel prior to dissolving.
  • the shell or shell portion preferably comprises a release modifying moldable excipient comprising a swellable erodible hydrophilic material.
  • the shell or a portion thereof functions as a barrier to prevent release therethrough of an active ingredient contained in an underlying core.
  • active ingredient is typically released from a portion of the core that is not covered by that portion of the shell, for example from a portion of the core in communication with one or more openings in the shell.
  • Such embodiments advantageously allow for control of the surface area for release of the active ingredient.
  • the surface area for release of active ingredient can be maintained substantially constant over time.
  • the release of at least one active ingredient follows substantially zero-order kinetics.
  • the shell preferably comprises a modified release composition comprising a water insoluble material, for example a water insoluble polymer.
  • the shell, or a shell portion functions as a delayed release coating to delay release of one or more active ingredients contained in an underlying core " or osmotic chamber.
  • the lag-time for onset of active ingredient release may be governed by erosion of the shell, diffusion of active ingredient through the shell, or a combination thereof.
  • the shell preferably comprises a release modifying moldable excipient comprising a swellable erodible hydrophilic material.
  • a dosage form according to the invention providing an immediate release of ibuprofen and an osmotic release of diphenhydramine is as follows. Part A. Preparation of the 200 mg Immediate-Release (IR) Ibuprofen Core Formulation:
  • Ibuprofen and sodium starch glycolate are delumped through a 30 mesh screen and said ingredients are mixed in a 2 qt. P-K blender for 5 minutes.
  • Colloidal silicon dioxide is also delumped through a 30 mesh screen and is added to the aforementioned mixture for blending for another 5 minutes.
  • Prescreened (through a 30 mesh screen) ibuprofen and sodium starch glycolate are mixed in a 2 qt. twin-shell blender for 5 minutes.
  • the final blend (from Step 1) is fed into the die of a rotary tablet press and is compressed into a tablet core under 2000 lb/in 2 of operating pressure.
  • the weight of compressed tablet is 213.0 mg, which contains 200.0 mg of ibuprofen.
  • the resulting diphenhydramine HCl granulation (440 mg) is then fed into a rotary tablet press equipped with round, concave compression punch and die units having a 0.4375" diameter.
  • the granulation is pressed into solid tablets using 2000 lb/sq. in. of compression force.
  • the fill material is prepared for application to the first core portion prepared in Part A.
  • the fill material comprises red gelatin for immediate release, and is made of the following ingredients: purified water, Opatint Red DD-1761, and 275 Bloom Pork Skin Gelatin added together as a mix of dry gelatin granules.
  • a gelatin slurry is formed from these ingredients and heated to 55°C to melt and dissolve the gelatin.
  • the gelatin solution is held at 55°C for approximately 3 hours (holding times at this temperature can generally range between about 2 and about 16 hours).
  • the solution is then mixed until uniform (about 5 to 15 minutes).
  • the gelatin solution is maintained at 55 0 C with continuous mixing during its use in the first thermal cycling molding module.
  • the molding unit comprises a single mold assembly made from an upper mold assembly portion comprising an upper mold cavity, and a lower mold assembly portion comprising a lower mold cavity.
  • the lower mold assembly portion is first cooled to 5°C.
  • the shell material of Part C is introduced into the lower mold cavity.
  • Two separate cores prepared, as described in aforementioned Parts A and B, are immediately inserted into two stations within the cavity.
  • the in-process dosage form is held in the chilled mold for 20 seconds to allow the shell material to harden.
  • the stations separate the two cores within the lower mold cavity by 1 mm.
  • a blank upper mold assembly portion is mated with the lower mold assembly portion.
  • the upper mold cavity comprises a small rod (0.1 mm in diameter x 1 mm in length) attached to its inner surface that contacts one station for core of Part A (200 mg ibuprofen tablet) to allow a portion of the dosage form to remain uncoated, and a second small rod that contacts one station for the core of Part B (Osmotic diphenhydramine tablet).
  • the shell material of Part C is introduced into the upper mold cavity.
  • the lower mold assembly portion which has been maintained at 5 0 C, is mated with the upper mold assembly portion in such a way that the cores of Part A (200 mg ibuprofen tablet) and Part B (Osmotic diphenhydramine tablet) is mated with the first core station of the upper mold assembly.
  • the shell material of Part C is introduced into the lower mold cavity and held at 5°C for 30 seconds to harden.
  • the fill material portion is injected into the upper mold portion and covers the portion of the core from Part A that was not previously covered by the shell to allow for immediate release. A small orifice remains over the core from Part B to allow for osmotic release.
  • the upper mold is held at 5°C for 60 seconds to allow the first and second fill material portions to harden.
  • the lower mold assembly portion is then removed and the finished dosage form, a molded caplet coated with a shell material and two fill materials, is ejected from the upper mold cavity.
  • the weight gain from the shell material i.e. the difference in weight between the finished dosage form and the core
  • Dosage forms of the invention are made in a continuous process using an apparatus comprising two thermal cycle molding modules linked in series via a transfer device as described at pages 14-16 of copending U.S. Application Serial No.09/966,939, the disclosure of which is incorporated herein by reference.
  • the dosage forms comprise two cores coated with a shell and a first and second fill portion.
  • the thermal cycle molding modules have the general configuration shown in Figure 3 and pages 27-51 of copending U.S. Application Serial No. 09/966,497, which depicts a thermal cycle molding module 200 comprising a rotor 202 around which a plurality of mold units 204 are disposed.
  • the thermal cycle molding modules include reservoirs 206 (see Figure 4) for holding the shell material, the first fill material, and the second fill material.
  • each thermal cycle molding module is provided with a temperature control system for rapidly heating and cooling the mold units.
  • Figures 55 and 56 of pending U.S. Application Serial No. 09/966,497 depict the temperature control system 600.
  • the transfer device has the structure shown as 300 in Figure 3 and described on pages 51-57 of copending U.S. Application Serial No. 09/966,414, the disclosure of which is incorporated by reference. It comprises a plurality of transfer units 304 attached in cantilever fashion to a belt 312 as shown in Figures 68 and 69. The transfer device rotates and operates in sync with the thermal cycle molding modules to which it is coupled. Transfer units 304 comprise retainers 330 for holding the cores as they travel around the transfer device.
  • the transfer device transfers the cores aforementioned in Part A and Part B to the second molding module, which applies the shell to the cores.
  • the second thermal cycle molding module is of the type shown in Figure 28A of copending U.S. Application
  • the mold units 204 of the second thermal cycle molding module comprise upper mold assemblies 214, rotatable center mold assemblies 212 and lower mold assemblies 210 as shown in Figure 28C. Cores are continuously transferred to the mold assemblies, which then close over the cores. At the beginning of the molding cycle (rotor at the 0 degree position) the mold assemblies are in the open position. Center mold assembly 212 as shown in copending U.S. Application Serial No. 09/966,497 as incorporated herein by reference, has received the compressed cores, for example from a compression module according to the invention transferred via a transfer device also according to the invention. As the rotor continues to revolve, the upper mold assembly 214 closes against center mold assembly
  • flowable material is injected into the mold cavity created by union of the mold assemblies to apply a shell from Part C to the first half of the dosage form.
  • the flowable material is cooled in the mold cavity.
  • the mold assemblies open with the partially coated dosage forms remaining in the upper mold assembly 214.
  • the center mold assembly rotates 180 degrees.
  • the mold assemblies again close and the uncoated portion of the compressed dosage form is covered with flowable material thus forming a shell having an opening aligned with the fill material, in a mold assembly that contains one or more protrusions, which prevent a portion of the cores from being covered.
  • the protrusions also contain nozzles for injecting the fill materials.
  • the protrusions retract following the application of the second portion of the shell from Part C, and the flowable fill material from Part D, heated to a flowable state in reservoirs 206, are injected into the uncoated portions over the core of Part A, forming the fill portions 16 as shown in Figure 2.
  • a small orifice remains over the core from Part B to allow for osmotic release.
  • a molding cycle is completed with setting or hardening of the shell and fill materials on the second half of the compressed dosage form.
  • the mold assemblies again open and the coated compressed dosage form is ejected from the molding module.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une forme pharmaceutique à libération modifiée permettant de fournir au moins un ingrédient pharmaceutiquement actif. Ladite forme pharmaceutique présente un premier noyau à libération immédiate pour un ingrédient actif, et un noyau osmotique ou une chambre osmotique contenant au moins un ingrédient pharmaceutiquement actif pouvant être identique à, ou différent de, celui contenu dans le premier noyau à libération immédiate. Une enveloppe possédant une ou plusieurs portions entoure le premier noyau à libération immédiate et le noyau ou la chambre osmotique. Ladite chambre osmotique inclut une couche barrière qui est substantiellement imperméable audit ingrédient pharmaceutiquement actif contenu dedans.
EP06851344A 2006-05-08 2006-05-08 Forme pharmaceutique osmotique Withdrawn EP2007346A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/009202 WO2008105752A1 (fr) 2006-05-08 2006-05-08 Forme pharmaceutique osmotique

Publications (1)

Publication Number Publication Date
EP2007346A1 true EP2007346A1 (fr) 2008-12-31

Family

ID=39595742

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06851344A Withdrawn EP2007346A1 (fr) 2006-05-08 2006-05-08 Forme pharmaceutique osmotique

Country Status (4)

Country Link
EP (1) EP2007346A1 (fr)
CN (1) CN101374497A (fr)
CA (1) CA2612989A1 (fr)
WO (1) WO2008105752A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3004070B1 (fr) 2013-04-05 2015-07-31 Bel Fromageries Procede d'enrobage de produits fromagers
CN107576653B (zh) * 2017-06-24 2023-03-17 中瀚利加（北京）科技有限公司 一种用于鉴定孕妇羊水的组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
TW235239B (fr) * 1992-11-20 1994-12-01 Pfizer
US6183466B1 (en) * 1998-08-21 2001-02-06 Alza Corporation Dosage form comprising a capsule
US6605302B2 (en) * 2001-07-17 2003-08-12 Osmotica Corp. Drug delivery device containing oseltamivir and an H1 antagonist
WO2004028511A1 (fr) * 2002-09-28 2004-04-08 Mcneil-Ppc, Inc. Forme galenique solide contenant du ketoprofene
CA2534371A1 (fr) * 2003-08-04 2005-02-10 Pfizer Products Inc. Formes posologiques d'inhibiteurs de la proteine de transfert d'ester de cholesteryle et d'inhibiteurs de la hmg-coa-reductase
CA2601762A1 (fr) * 2005-02-03 2006-08-10 Pfizer Products Inc. Formes de dosage assurant la liberation controlee et instantanee d'inhibiteurs de proteines de transfert d'ester de cholesteryle et la liberation instantanee d'inhibiteurs de hmg-coa reductase
US20060233882A1 (en) * 2005-04-15 2006-10-19 Sowden Harry S Osmotic dosage form
EP1749519A1 (fr) * 2005-08-05 2007-02-07 Schering Aktiengesellschaft Forme galénique à libération prolongée pH-indépendant pour les substances actives avec une solubilité pH-dépendante

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008105752A1 *

Also Published As

Publication number Publication date
CN101374497A (zh) 2009-02-25
WO2008105752A1 (fr) 2008-09-04
CA2612989A1 (fr) 2007-11-08

Similar Documents

Publication Publication Date Title
US7416738B2 (en) Modified release dosage form
US8673352B2 (en) Modified release dosage form
EP1545472B1 (fr) Forme galenique a liberation modifiee comprenant deux noyaux et un orifice
KR20060049497A (ko) 개구를 갖는 쉘을 포함하는 속방형 투여 형태
US20080206337A1 (en) Method of making dosage forms comprising polymeric compositions
CA2500311A1 (fr) Formes de dosage a liberation modifiee
US20060233882A1 (en) Osmotic dosage form
WO2008105752A1 (fr) Forme pharmaceutique osmotique
US20050196446A1 (en) Polymeric compositions and dosage forms comprising the same
EP2046302A2 (fr) Forme pharmaceutique à libération modifiée
WO2009023006A2 (fr) Forme pharmaceutique à libération modifiée
US20050196447A1 (en) Polymeric compositions and dosage forms comprising the same
US20050196442A1 (en) Polymeric compositions and dosage forms comprising the same
EP1729738B1 (fr) Compositions polym riques et formes posologiques contenant ces compositions
KR20070017128A (ko) 중합체성 조성물 및 이를 포함하는 투여 형태
AU2002337772A1 (en) Modified release dosage forms
MXPA05003281A (es) Formas de dosis de liberacion modificada con dos nucleos y una abertura.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RBV Designated contracting states (corrected)

Designated state(s): DE ES FR GB IT PL

17Q First examination report despatched

Effective date: 20100507

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100918